Navigation Links
101 liver cancer drug candidates pave the way to personalized medicine

The heart disease drug perhexiline is one of 101 compounds predicted to prevent cancer growth in most patients suffering from our most common liver cancer, HCC. This is an outcome from a novel simulation-based approach using personal sets of proteins of six HCC patients.

"This is the first time personalized models have been used to find and evaluate new potential drugs," says Professor Jens Nielsen at Chalmers University of Technology. --

Our most common liver cancer, Hepatocellular carcinoma, HCC, causes more than half a million deaths worldwide every year. If the cancer cannot be surgically removed the disease is usually deadly within 3-6 months. Only 30 percent of the patients respond to the best existing drug, sorenafib. This new research now identifies 101 drug candidates predicted to prevent the cancer growth in all six studied patients, which raises hope of developing a drug helping all HCC-patients.

Cancer cells modify their metabolism in order to breed. To understand these diverse mechanisms, what metabolic enzymes are involved, when and how, has been a major focus in medicine in order to identify novel drug targets. However, this is quite a challenging task, since HCC not only involves a large number of interplays between different biological pathways, but also significant individual variations.

Finding the candidates

Average models don't give sufficiently good answers. To take the individual variations into account the researchers generated personalized proteomics data for HCC patients using the antibodies produced in the Human Protein Atlas project (read more below). The researchers then generated individual computer models for six HCC patients based on their entire, personal set of proteins and a generic map of human metabolism, which had been produced in an earlier project.

"I am excited to see how we have managed to successfully transfer our modelling approaches on yeast to study cancer metabolism," says Dr Rasmus gren, shared first author of the paper.

The six personal models were then used to find potential new anticancer drugs. One of the most common types of anticancer drugs is so called antimetabolites. Antimetabolites prevent the use of one or more metabolites (the small molecules that act and are produced, and whose interplay together constitute a full metabolism) by stopping the catalyzing enzymes. By simulating the effect of all possible antimetabolites more than 3000 compounds the computer generated potential anti-cancer drugs which could be effective in inhibiting tumor growth.

Furthermore, the researchers simulated the effect of these antimetabolites on 83 major healthy cell types in human body to predict their toxic effects. This led to the identification of 101 antimetabolites which were predicted to prevent cancer growth in all six studied HCC patients, whereas 46 antimetabolites inhibited tumor growth only in one or a few of the patients. All 147 were predicted to not be overly toxic to healthy cells.

Clinical tests

The general validity of the approach can be extended by running personalized models for more patients.

"With this approach we can find and evaluate new potential drugs, some that could be used for general treatment of HCC, and others that are highly specific for each HCC patient. We can also predict false positive drug targets that would not be effective in all patients. This would lead to more targeted and efficient cancer treatment," says Dr Adil Mardinoglu, shared first author of the paper.

One of the antimetabolites was tested in vitro on a liver cancer cell line. The tested compound, perhexiline, had an effect on viability comparable to sorafenib, demonstrating the predictive power of the computer models. Perhexiline is a drug approved for heart disease, and the potential to use it for HCC is of course interesting. As a continuation of this study, perhexiline will be tested on other cancer cell lines, since the researchers believe it may inhibit growth in other types of cancer as well. The initial experiments look very promising.

Read the article in Molecular Systems Biology: Identification of anticancer drugs for hepatocellular carcinoma through personalized genome-scale metabolic modeling


Mass production of personalized models with new algorithm

Tinit, a new algorithm for automatic reconstruction of personalized models, was recently developed at Chalmers University of Technology, branded as tINIT. Compared to previous algorithms it allows reconstruction of functional and simulation ready models. All the tools for have been made publically available in the so called Raven toolbox.

Proteomics data in Human Protein Atlas

All of the models were generated based on the proteomics data generated in Human Protein Atlas, HPA. The Human Protein Atlas project is a world leading effort to systematically explore the human proteome in 46 different types of normal tissue and 216 different cancer tissues representing the 20 most common forms of human cancer. The atlas was recently used to generate a virtual map of human metabolism, in a collaborative project between Chalmers University of Technology and researchers at SciLifeLab. This virtual map of human cell metabolism has the most comprehensive list of the entire set of known biochemical reactions which occurs in human body. The map contains more than 8,000 reactions and 3,765 associated genes, and it represents a great resource for systems biologists working in human disorders related to metabolism.

Read the article in Molecular & Cellular Proteomics: Analysis of the Human Tissue-specific Expression by Genome-wide Integration of Transcriptomics and Antibody-based Proteomics

Drug targets and biomarkers also for other liver conditions

The same type of modelling (however using an average model) has previously been used to investigate the most common liver disease, non-alcoholic fatty liver disease. This resulted in predictions of new drug targets, new biomarkers for diagnosis, as well as suggestions for dietary interventions.

Read more about that study in the Chalmers' news item Computer model takes us closer to treatment of our most common liver disease, or the Nature Communications article Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease.


Contact: Christian Borg
Chalmers University of Technology

Related biology news :

1. Nanotherapy: Treating deadly brain tumors by delivering big radiation with tiny tools
2. Crestor Delivers Latest LDL-C Targets in High-Risk Patients at Lower Doses than Other Statins
3. Researchers unravel genetic mechanism of fatty liver disease in obese children
4. Commonly used diabetes drug may help to prevent primary liver cancer
5. Ben-Gurion U. licenses drug delivery platform for central nervous system diseases to NY biotech firm
6. Gut microbiota transplantation may prevent development of diabetes and fatty liver disease
7. Gallbladder shown as potential stem cell source for regenerative liver and metabolic disease
8. Family history of liver cancer increases risk of developing the disease
9. Modest alcohol intake associated with less inflammation in patients with common liver disease
10. Delivery of gene-therapy for heart disease boosted 100-fold; now in 100-patient trial
11. Cancerous tumors deliver pro-metastatic information in secreted vesicles
Post Your Comments:
Related Image:
101 liver cancer drug candidates pave the way to personalized medicine
(Date:8/15/2017)...   ivWatch LLC , a medical device company focused on ... receipt of its ISO 13485 Certification, the global standard for medical ... Standardization (ISO®). ... Continuous Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as ...
(Date:6/23/2017)... N.Y. and ITHACA, N.Y. ... ) and Cornell University, a leader in dairy research, ... with bioinformatics designed to help reduce the chances that ... With the onset of this dairy project, Cornell University ... Consortium for Sequencing the Food Supply Chain, a food ...
(Date:5/16/2017)...  Veratad Technologies, LLC ( ), an innovative ... verification solutions, announced today they will participate as a ... thru May 17, 2017, in Washington D.C.,s ... Identity impacts the lives of billions ... evolving digital world, defining identity is critical to nearly ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... 11, 2017 , ... Disappearing forests and increased emissions are the main causes ... each year. Especially those living in larger cities are affected by air pollution related ... the most pollution-affected countries globally - decided to take action. , “I knew I ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... FirstHand program has won a US2020 STEM Mentoring Award. Representatives of the FirstHand ... Excellence in Volunteer Experience from US2020. , US2020’s mission is to change the ...
(Date:10/10/2017)... ... October 10, 2017 , ... The ... prestigious awards honoring scientists who have made outstanding contributions to analytical ... during Pittcon 2018, the world’s leading conference and exposition for laboratory science, which ...
(Date:10/9/2017)... (PRWEB) , ... October 09, ... ... published on October 5, 2017, in the medical journal, Epilepsia, Brain Sentinel’s ... the gold standard, video EEG, in detecting generalized tonic-clonic seizures (GTCS) using ...
Breaking Biology Technology: